Skip header Skip to main content
A magnifying glass over a pill.

What is a Poison Pill?

Written by The Inspired Investor Team | Published on May 25, 2022

Investing Academy.  Knowledge Supports Success. Visit now.

Corporate takeovers are often friendly arrangements, with negotiated terms that both shareholders and management support. However, not every company wants to be taken over — which is when we often start to see the term poison pill making headlines. But what exactly does it mean? Let's take a look.

What is a poison pill?

A poison pill, also known as a shareholder rights plan, is a defensive strategy that companies can implement to protect themselves from being taken over when they don't want to be acquired. Fun fact: The name apparently comes from the poison pill that spies would carry around in case they were captured by their enemies.

In a hostile takeover, a poison pill is an action taken by the target company to make it less appealing to the bidder. Typically, a poison pill allows the company being targeted to flood the market with new shares, thereby diluting the hostile bidder's ownership stake and making a takeover offer by them that much harder to swallow — at times, prohibitively so.

How does a poison pill work?

The most common type of poison pill is known as a "flip-in." This type gives all shareholders of the target company (except for the hostile bidder) the right to purchase additional shares at a discounted rate when a potential acquirer reach a certain ownership level. Typically, poison pills are triggered when a hostile bidder hits that ownership threshold, which often between 10 and 15 per cent but can vary.

A less common poison pill tactic is known as the "flip-over." If a hostile takeover is successful, a flip-over plan would allow shareholders of the target company to buy shares of the acquiring company at a discount. This tactic would dilute the value of the shares of the acquiring company, which could discourage the hostile bidder from following through.

Is it a good idea?

There are many pros and cons for companies to consider when adopting a poison pill. We'll touch on a couple of key ones here.

Perhaps the most obvious upside is a poison pill's potential to block a hostile takeover, maintaining control and management of the company. It can also give management time to seek better offers. On the downside, when new shares are issued at a discount, the value of the stock is affected and investors would be forced to purchase new shares in order to maintain the same stake they held previously. As well, a successful poison pill plan would mean shareholders miss out on a likely hefty premium offered in a hostile bid.

A poison pill is typically used as a last resort by companies that do not want to be acquired. According to the New York Times, the poison pill was developed in the 1980s as a way for company leaders to defend their businesses from being acquired. Hostile takeovers, it says, aren't as common today as they were in the '80s because potential acquirers now assume companies have poison pills in place.

RBC Direct Investing Inc. and Royal Bank of Canada are separate corporate entities which are affiliated. RBC Direct Investing Inc. is a wholly owned subsidiary of Royal Bank of Canada and is a Member of the Investment Industry Regulatory Organization of Canada and the Canadian Investor Protection Fund. Royal Bank of Canada and certain of its issuers are related to RBC Direct Investing Inc. RBC Direct Investing Inc. does not provide investment advice or recommendations regarding the purchase or sale of any securities. Investors are responsible for their own investment decisions. RBC Direct Investing is a business name used by RBC Direct Investing Inc. ® / ™ Trademark(s) of Royal Bank of Canada. RBC and Royal Bank are registered trademarks of Royal Bank of Canada. Used under licence.
© Royal Bank of Canada 2022.

Any information, opinions or views provided in this document, including hyperlinks to the RBC Direct Investing Inc. website or the websites of its affiliates or third parties, are for your general information only, and are not intended to provide legal, investment, financial, accounting, tax or other professional advice. While information presented is believed to be factual and current, its accuracy is not guaranteed and it should not be regarded as a complete analysis of the subjects discussed. All expressions of opinion reflect the judgment of the author(s) as of the date of publication and are subject to change. No endorsement of any third parties or their advice, opinions, information, products or services is expressly given or implied by RBC Direct Investing Inc. or its affiliates. You should consult with your advisor before taking any action based upon the information contained in this document.

Furthermore, the products, services and securities referred to in this publication are only available in Canada and other jurisdictions where they may be legally offered for sale. If you are not currently resident of Canada, you should not access the information available on the RBC Direct Investing Inc. website.

EXPLORE MORE
Several laptops, keyboards and mouses facing different directions arranged in a pattern

ETF Trends from the RBC Capital Markets Trading Floor - March 2025

Here’s what we saw on the trading floor in March 2025

Magnifying glass revealing charts and graphs over a yellow background

What do Analyst Estimates Really Mean, and How do They Affect Stock Prices?

Making these projections might seem like a black art, but there’s science behind it too

Multiple open laptops with charts on the screens sitting on a green surface

ETF Trends from the RBC Capital Markets Trading Floor

Here’s what we saw on the trading floor in January 2025

You Know More Than You Think

A guide to investing in stocks.
Find out more